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Abstract
Background:  Clustering analysis of microarray data is often criticized for giving ambiguous results
because of sensitivity to data perturbation or clustering techniques used. In this paper, we describe a new
method based on principal component analysis and ensemble consensus clustering that avoids these
problems.
Results: We illustrate the method on a public microarray dataset from 36 breast cancer patients of whom
31 were diagnosed with at least two of three pathological stages of disease (atypical ductal hyperplasia
(ADH), ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC). Our method identifies an
optimum set of genes and divides the samples into stable clusters which correlate with clinical classification
into Luminal, Basal-like and Her2+ subtypes. Our analysis reveals a hierarchical portrait of breast cancer
progression and identifies genes and pathways for each stage, grade and subtype. An intriguing observation
is that the disease phenotype is distinguishable in ADH and progresses along distinct pathways for each
subtype. The genetic signature for disease heterogeneity across subtypes is greater than the heterogeneity
of progression from DCIS to IDC within a subtype, suggesting that the disease subtypes have distinct
progression pathways.
Our method identifies six disease subtype and one normal clusters. The first split separates the normal
samples from the cancer samples. Next, the cancer cluster splits into low grade (pathological grades 1 and
2) and high grade (pathological grades 2 and 3) while the normal cluster is unchanged. Further, the low
grade cluster splits into two subclusters and the high grade cluster into four. The final six disease clusters
are mapped into one Luminal A, three Luminal B, one Basal-like and one Her2+.
Conclusion: We confirm that the cancer phenotype can be identified in early stage because the genes
altered in this stage progressively alter further as the disease progresses through DCIS into IDC. We
identify six subtypes of disease which have distinct genetic signatures and remain separated in the
clustering hierarchy. Our findings suggest that the heterogeneity of disease across subtypes is higher than
the heterogeneity of the disease progression within a subtype, indicating that the subtypes are in fact
distinct diseases.
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Background
One out of ten women who reaches the age of ninety will
have had breast cancer in her lifetime. Most tumors are
treated with a combination of surgery, radiation therapy,
and adjuvant systemic therapy (hormonal therapy, chem-
otherapy, and/or biological therapy). 60–80% of tumors
express the estrogen receptor ER and respond to treatment
with hormonal agents such as aromatase inhibitors or
Tamoxifen [1,2]. 20–40% have amplification of the Her2
gene [3] which is a marker of increased recurrence rates
and poorer prognosis. The outcome of these Her2+
tumors can be improved by the addition of the human-
ized anti-Her2 antibody trastuzumab (Herceptin) to their
treatment regimen. 10–15% of tumors neither express the
estrogen receptor nor harbor Her2 amplification and have
a characteristic gene expression profile [4]. These cancers,
called Basal-like [5,6], are high grade aggressive malignan-
cies with poor overall prognosis, and at present there is no
targeted therapy for them. In spite of these classifications
and treatment choices, therapy is confounded by the fact
that tumors with similar histopathology often have diver-
gent course and varied response to therapy [7].
Microarrays have the potential to shed light on this pic-
ture because of their ability to provide a snapshot of the
genetic state of the cell. In principal, they should be able
to identify the genes and pathways altered in cancer initi-
ation, progression and metastasis. This promise has
resulted in microarray technology being aggressively pur-
sued by researchers, hospitals and pharmaceutical compa-
nies to get an improved understanding of the disease
process, better diagnostic protocols, new drugs, and new
treatment regimens. However, the success of these efforts
has been limited by practical considerations. The biggest
limitation is that the results from microarray studies are
sensitive to noise and analysis method [8]. This often
leads to ambiguous results and biologically non-intuitive
genes and pathways for stratification [8]. Efforts to use
microarray data to identify the underlying biology of dis-
ease progression and help characterize the disease pheno-
type have met with limited success. In this paper, we
develop and give results from a robust method which
addresses the issues outlined above. We first use Principal
Component Analysis (PCA) [9] to identify the overall
structure of clusters in the data and to select the subset of
genes that distinguish the clusters. We then use this set of
genes and a new consensus ensemble k-clustering tech-
nique, which averages over several clustering methods
and many data perturbations, to identify strong, stable
clusters. We also define a simple criterion to find the opti-
mum number of clusters and a method to identify robust
markers for disease progression within each cluster.
Results
Applied to a breast cancer microarray data set, our method
results in stable lists of genes and pathways that distin-
guish high and low grade tumors. It also identifies other
robust gene sets which mark progression of disease from
DCIS or ductal carcinoma in-situ to IDC or invasive ductal
carcinoma. The clusters paint a portrait of the disease at
varying levels of granularity. When the data is divided into
two clusters, the normal samples form one cluster and the
disease samples form another. At the next level of cluster-
ing, the low grade and high grade samples separate. The
optimal number of clusters is seven, corresponding to two
sub-clusters (LG1 and LG2) of the low grade samples and
four (HG1-HG4) of the high grade samples. These sub-
clusters are well separated by a strong set of markers which
are able to distinguish them with sensitivity and specifi-
city in the 80–100% range. We identify the genes and
pathways that mark disease progression in each sub-clus-
ter. A major result of our analysis is that each sub-cluster
contains samples from non-invasive and invasive tumors from
the same patient. This suggests that within each grade of
breast cancer, different groups of patients progress to the
same final phenotype along different pathways. This
result suggests that the sub-clusters identified here are dis-
tinct diseases. If validated on larger datasets with larger
gene-sets, it would have significant implications for dis-
ease identification and treatment.
Using the genes specific to each cluster and ER, PR, Her2+
levels in the data, we can place the clusters into the stand-
ard categories used to classify breast cancer as defined in
[5]. We find that the low grade clusters correspond to one
Luminal A subtype and one Luminal B subtype. The high
grade samples correspond to two additional Luminal B
subtypes, one Her2+ subtype and one Basal-like subtype.
Description of data
The data was obtained from [10] and consisted of samples
from 36 breast cancer patients of which 31 were diag-
nosed with at least two out of three pathological stages of
disease: atypical ductal hyperplasia or ADH, ductal carci-
noma in situ or DCIS and invasive ductal carcinoma or
IDC respectively. The remaining 5 patients were diag-
nosed to have pre-invasive disease (ADH) only. Microar-
ray analysis was also done for samples collected from
normal breast epithelial tissue extracted from three
healthy women during routine mammoplasty. From the
cancer patients, normal as well as disease samples were
collected from as many different stages of disease (ADH,
DCIS, IDC) as possible. These samples were harvested in
triplicate using laser capture micro-dissection (Arcturus,
CA), taking care to avoid contamination between cells of
different stages from the same patient. Each sample was
analyzed in duplicate with a 12,000 gene cDNA microar-
ray. It was determined that the "normal cells" from cancerBMC Bioinformatics 2007, 8:291 http://www.biomedcentral.com/1471-2105/8/291
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patients were highly similar to the normal epithelium of
the three disease free patients. This suggested that the nor-
mal samples from cancer patients could be used as a base-
line to determine disease state and progression.
The data provided in [10] consisted of the expression lev-
els of 1940 genes across 93 samples. 32 of these were from
disease free or normal tissue, 8 were ADH samples, 30
were DCIS samples and 23 were IDC samples. The 1940
genes (out of the 12,000 genes on the microarray) were
selected in [10] by their ability to distinguish "normal
cells" and each of the disease stages ADH, DCIS and IDC
using a linear discriminant function. The patients were
further classified by pathological analysis into 3 categories
based on the tumor grade: grade I (18 patients), grade II
(22 patients) and grade III (19 patients). The mapping of
sample labels to stage and grade and a patient identifier is
given in Additional File 1. This table also includes the clas-
sification of the samples into the disease subtypes using
the methods described in this paper.
Flow chart of the analysis method Figure 1
Flow chart of the analysis method: The method starts with data normalization and proceeds to the identification of pre-
dictive genes using principal component analysis to ensemble clustering into k = 2,3,... clusters. The clusters are then analyzed 
to identify their characteristic gene patterns which are then used to find altered pathways associated with the disease process.
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The flow chart of our analysis method is presented in Fig-
ure 1. First the dataset was normalized and missing entries
imputed robustly. Next, PCA was used to find the genes
which accounted for most of the variation in the data. The
optimal number of clusters kopt in the data was estimated
using gap statistics [11] and silhouette scores [12]. Next a
variety of clustering techniques and data perturbations are
averaged to divide the data into 2,3,...kopt clusters.
We estimate the number of clusters using the silhouette
scores and gap statistics. This provides a range for the
number of clusters. In our case, the range was 6–7 so we
chose kmax = 7. This range is compared to the optimum
number of clusters provided by the EM mixture modeling
approach. (in Monti et al [17], AutoClass was used for this
analysis. In our study we use the EMclust package in R
[13]). We then create ensemble consensuses of k clusters
for each k = 2, 3,..kmax as follows:
For each k, we integrate the clustering results across clus-
tering methods and perturbations into an agreement
matrix. To obtain a global optimum clustering solution,
Hierarchical nature of breast cancer progression Figure 2
Hierarchical nature of breast cancer progression: Consensus ensemble k-clustering tree reveals the recursive splitting 
of breast cancer subtypes. At k = 2, the ensemble clustering split the normal samples from the disease samples. At k = 3, the 
normal cluster remained unchanged and the disease samples split into low grade (pathological grades 1 and 2) and high grade 
(pathological grades 2 and 3). The optimum number of clusters in the data was seven corresponding to one normal cluster, 
two low grade clusters and four high grade clusters. Between two k values, the samples did not switch clusters, indicating that 
the hierarchical structure in the figure is a strong property of the data. In the final disease clusters, samples from the same 
patient microdissected from DCIS and IDC lesions were found in the same cluster, indicating that the disease subtypes are 
more heterogeneous than disease progression within a subtype.
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we apply simulated annealing to the agreement matrix at
each k to sort the samples into the best k clusters, which
appear as blocks along the diagonal in the sorted agree-
ment matrix. The agreement matrix cost function used in
simulated annealing optimizes between the similarity
inside the clusters and the dissimilarity between different
clusters for each k. Once the data is clustered by simulated
annealing into k pieces, we compute the silhouette scores
for these k clusters (in addition to other measures such as
the internal diameter, external dissimilarity etc) using the
fpc package from R.
We stop at k = kopt clusters beyond which the "quality" of
the clusters obtained from the agreement matrix begins to
deteriorate. This is assessed by analyzing the accuracy of
cluster membership assignments using weighted voting
and kNN on single and multiple gene markers (patterns)
which distinguish the clusters. We stop clustering when
the accuracy of such an assignment falls below 75%.
Principal Component Analysis
PCA showed that 50% of the variation in the data was rep-
resented by the first 5 PCs and 85% by the first 32 PCs. We
identified 207 genes as those with highest absolute value
(top 1st quartile) in the coefficients of the first 32 eigen-
vectors as representative of most of the data variation.
These thresholds were estimated through a calibration
step whose aim was to optimize the overall cluster mem-
bership assignment for the optimal number of clusters
identified in the data restricted to the selected genes.
Consensus ensemble k-clustering
Gap statistic and the silhouette scores [11,12] estimated k
= 7 as the optimal value for the number of clusters in the
data. The data was divided into k = 2, 3,...,7 clusters by
using the 207 genes identified by PCA and by applying
Consensus Ensemble k-clustering (see the Methods sec-
tion below).
The results are shown schematically in Figure 2. At k = 2,
the samples separated into a "normal" (N) group, which
contained all the normal samples and one ADH sample
(from patient id 210), and a "breast cancer" (BCA) group,
which contained all the remaining breast cancer samples.
At k = 3, the normal group was unaltered but the BCA
group split into a low grade (LG) tumor group containing
18 samples labeled grade 1 and 9 samples labeled grade 2,
and a high grade (HG) tumor group containing 13 sam-
ples labeled grade 2 and 19 samples labeled grade 3. As k
increased progressively from 4 through 7, the LG group
split into 2 distinct subgroups (labeled LG1 and LG2 in
Figure 2) and the HG group split into 4 distinct subgroups
(labeled HG1-HG4).
Even though the clusters at each level were determined
independently, at clustering level k+1, two clusters always
emerged as splits of a parent cluster at level k, while the
remaining k-1 clusters were inherited unchanged from the
previous level k. This shows that the data inherently con-
tains a hierarchy of detail, providing portraits of disease at
different levels of clustering resolution. The separation of
samples into "normal" and "disease" at k = 2, the split of
the disease samples into "low" and "high" grades at k = 3
and so on, strongly suggests that disease progression is a
hierarchical process and is readily and robustly identifia-
ble by our clustering procedure.
Table 1 shows the characteristics of the samples in these
groups with respect to stage, ER, PR, Her2, lymph node
and grade status for k = 2,3 and 7. These subgroups of LG
and HG are strongly dissimilar with respect to the cluster
agreement matrix, which is shown in Figure 3. The HG1
subgroup is particularly different from the other HG sub-
groups (as is also evident in Figure 2). All samples in it are
ER-, PR- and mostly Her2-. The HG2 subgroup has a
mixed ER signature, and the HG3 and HG4 subgroups
consist mostly of ER positive samples. Based on these and
other signatures (see below), we identify LG1 as Luminal
A; LG2, HG3, HG4 as Luminal B; HG1 as Basal-like and
HG2 as Her2+.
Genes discriminating low and high grade tumors
Using a non-stringent Signal-to-Noise-Ratio (SNR) test
(permutation p-value p = 0.10) we found 223 gene mark-
ers which distinguish the group LG from HG. A subset of
10 markers was selected based on their performance on
leave-one-out cross-validation experiments for weighted
voting (WV) and k-Nearest Neighbors (kNN) classifica-
tion models. The models trained on these 10 markers pro-
duced only 1 false positive error (DCIS #79) and 1 false
negative error (DCIS #183) in leave-one-out experiments.
Using the SNR test and leave-one-out experiments for the
WV and kNN models, we identified 10 markers which dis-
tinguish the LG samples from all others (HG and N) with
90% accuracy. We find that RBSK, Homo sapiens cDNA
FLJ12924 fis, clone NT2RP2004709 and CRIP1 are up-
regulated in the LG group, and EYA2, ANXA1, RUNX3,
DKFZp762A227, GPRC5B are down-regulated in the LG
group.
For the high grade cluster, the classification accuracy was
97% with 3 false positive and zero false negative errors.
The top markers up-regulated in HG are TRAM, HSPC150,
TACC3, CDKN3, UBE2C, and top markers down-regu-
lated in HG are X123, GNG7, SH3BGRL2, LOH11CR2A
and Homo sapiens, clone IMAGE:3917549 mRNA, partial
cds.BMC Bioinformatics 2007, 8:291 http://www.biomedcentral.com/1471-2105/8/291
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Low grade substructure
Table 1 shows that both LG1 and LG2 are ER+, PR+ and
Her2-, which explains their pathological classification as
low grade. We note that LG2 has a greater fraction of
Grade II samples compared to LG1 which identifies LG2
as the more aggressive subtype. The genes that discrimi-
nate LG1 from other low and high grade subgroups
include the down-regulated BIRC5 (survivin) gene, which
inhibits apoptosis and is suggested as a marker of poor
prognosis in different cancer types [14,15]. Two others are
ACAA1 and ACOX1 enzymes, which are involved in fatty
acid metabolism. LG2 markers include 190 genes, among
which are many oncogenes, (BCL2 (down, breast cancer
poor prognosis marker), RAD51 (up), EGFR (up), RUNX3
(up), BCL9 (down) and VAV3 (down) and tumor sup-
pressor gene NME1 (up). The ER and Her2 status suggest
that both LG1 and LG2 are Luminals in the standard
nomenclature [5], with LG2 presenting more aggressive
features than LG1. On the basis of this, in the nomencla-
ture of [5], we identify LG1 as the Luminal A subtype and
LG2 as one Luminal B subtype.
High grade substructure
As seen in Table 1, all the samples in the HG1 subgroup
were ER and PR negative while those in the HG3 and HG4
subgroups were mostly ER and PR positive. The HG2 sam-
ples had mixed ER and PR signatures. The HG1 subgroup,
which is the worst prognosis group based on clinical char-
acteristics, had as discriminatory markers the genes BCL2
(up), RAD51 (down), GSTP1 (down) and RRM2 (down).
HG2 markers also include up-regulated BCL2 (1.7 fold
less up-regulated than in HG1) and down-regulated
RRM2.
The HG3 markers, include a group of down-regulated
genes in chromosomal region 17q23-25 which harbors
the ERBB2 amplicon 17q 22.24. These genes are KPNA2
(17q23.1-q23.3), amplified in breast cancer 1 (AIBC1,
17q23.2), Bcl-2 inhibitor of transcription (BIT1,
17q23.2), hypothetical protein TANC2 (17q23.3), and
two proteosome protein PSMC5 (17q23-Q25) and
PSMD12 (17q24.2). This suggests the possibility that
patients in the HG3 subgroup might have a re-arrange-
ment or deletion of genes around the Her2 gene leading
to loss of regulation or function for these genes which
might explain why only 15% of HG3 patients are Her2+,
while 53% are Her2- and 15% are undetermined. Since
IHC data for the ERBB2 gene was not made available in
[10], the down-regulation of the ERBB2 amplicon genes
in the HG3 samples identifies its clinical signature as
Her2-.
The most notable HG4 marker was a down-regulation in
the transforming growth factor beta receptor II (TGFBR2).
Mutations in this gene have been associated with the
development of various types of tumors. The over-expres-
sion of this gene was found to be associated with poor
prognosis breast tumors. Overall, gene markers and clini-
cal parameters lead to the conclusion that among the high
grade subgroups HG4 is probably the best prognosis
group composed of Grade II tumors that are all ER+ and
PR+.
Table 1: Clinical characteristics of k = 2,3,7 clusters: The ER, PR, Her2, Node, stage and grade status of the samples in each cluster are 
shown for k = 2,3 and 7. ND stands for "Not Determined". At k = 2, the clustering splits the data into normal samples and disease 
samples (BCA), except for one ADH which is classified with the normals. At k = 3, the BCA samples split into high grade (grade 2 or 3) 
and low grade (grade 1 or 2) categories. At k = 7, the low grade samples split into two clusters LG1, LG2 and the high grade into four: 
HG1 – HG4. The HG1 samples are all ER-, PR- and mostly Her2-. The HG3 and HG4 clusters are mostly ER+, PR+, Her2-. The HG2 
cluster has mixed ER, PR and Her2 signatures. Using the Sorlie et al classification, we identify HG1 as the Basal-like subtype; LG1 as 
Luminal A; LG2, HG3 and HG4 as Luminal B and HG2 as the Her2+ subtype. When the sum of the entries for ER/PR/Her2/Node/
Grade do not add up to the size of the cluster, it is because the corresponding information was missing in the dataset [10].
Cluster level k Group Size Stage ER PR Her2 Node Grade
ADH DCIS IDC N Pos Neg ND Pos Neg ND Pos Neg ND Pos Neg 1 2 3
2N 3 3 1 3 2
BCA 60 7 30 23 47 10 3 42 15 3 10 37 9 44 14 18 22 19
3 LG 28 7 13 8 26 2 21 5 2 4 18 6 20 8 18 9
HG 32 17 15 21 10 1 21 10 1 6 19 3 24 6 13 19
7L G 1 1 1 4 5 2 1 1 8 3 1 1 07 4 9 2
L G 21 7 3 8 6 1 5 21 32 23 8 61 349 7
HG1 5 2 3 5 5 1 4 3 5
H G 2 1 0 7 3 7 35 53 4 1 9 1 2 8
H G 31 3 6 7 1 02 11 2 1 2 7 21 03 76
HG4 4 2 2 4 4 4 2 2 4BMC Bioinformatics 2007, 8:291 http://www.biomedcentral.com/1471-2105/8/291
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Heatmap of agreement matrix for seven clusters Figure 3
Heatmap of agreement matrix for seven clusters: The agreement matrix for NS samples is an NS × NS matrix whose 
entries are the fraction of cases across replicates for which two samples fall into the same cluster. Red/green represent high/
low fractional values across clustering methods and data perturbation replicates. The normals and the LG1 and LG2 are clearly 
well separated while the HG1, HG2, HG3 and HG4 separation is weaker. We find that the optimum number of clusters using 
gap-statistics oscillates between 6 and 7 with the HG3 and HG4 clusters merging at k-6.
-1.0 1.0 0.0
LG1 LG2 N HG1 HG2 HG3 HG4BMC Bioinformatics 2007, 8:291 http://www.biomedcentral.com/1471-2105/8/291
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Based on these observations, we identify HG1 as Basal-
like [5,6], HG2 as Her2+, and HG3 and HG4 as additional
subtypes of Luminal B [5].
Figure 4 presents a heatmap showing the classification
into subtypes using top 10 gene markers for each. Each set
of markers distinguished a given subtype from all the
other subtypes with an accuracy above 90% in leave-one-
out experiments for WV and kNN classification models
(see Table 2). The signatures of the subgroups LG1-HG4
stand out clearly. Table 2 presents the sensitivity and spe-
cificity scores on leave-one-out cross-validation experi-
ments for WV models. Note that the specificity ranges
from 91–97%, and the sensitivity from 82–100%. The
results for kNN are very similar. We note that these results
may be slightly inflated because the subtypes were discov-
ered on the same dataset on which we did the sensitivity/
specificity analysis.
Figures 5 and 6 present heatmaps using the top 10 upreg-
ulated markers which classify the tumors by grade and
stage respectively. Since the sample sizes are small, the p
values for each classification were obtained using permu-
tation experiments and the FDR rates inferred from these.
The FDR values for the genes in Figure 5 are 0.6 for LG, 0.2
for HG and for the genes in Figure 6 are 0.02 for LG1, 0.2
for LG2, 0.2 for HG1, 0.5 for HG2, 0.06 for HG3 and
0.002 for HG4. It should be noted that the sample sizes in
this study are small. Consequently, these results are to be
considered as hypothesis generating. All these results
should be validated on larger data sets. Figure 7 maps the
genes identified for progression in different grades into
pathways for disease progression using the classification
of Hanahan and Weinberg [16,17].
Discussion and conclusion
The use of ensemble consensus clustering is absolutely
critical to distinguish the subtypes. PCA by itself could
identify a collection of useful markers, but could not iden-
tify the rich stratification discovered by consensus ensem-
ble  k-clustering. Hierarchical clustering by itself would
separate the samples into clusters but the stratification
would be very sensitive to bootstrap, indicating that the
clusters are unstable to data perturbation. Robustness of
clustering is only obtained by averaging over many clus-
tering techniques and data perturbations as is done in the
ensemble consensus clustering technique used here.
Our results show that progression of the disease from
non-invasive to invasive status occurs along different
pathways. Progression in the low-grade groups seems to
correlate with changes in metabolic and transportation
pathways, while in the high grade groups it is related to
alterations in cell-cycle and signaling pathways, with dis-
tinct subsets of genes involved in each.
Table 3 presents a summary of the significant pathways
involved in the low-and high grade subgroups. We find
that the differences between the levels in the DCIS and
IDC groups are quite subtle and the accuracy of leave-one-
out experiments of simple WV models trained to distin-
guish between DCIS and IDC in each group ranges
between 60–70%.
The main observation of the original paper of Ma et al
[10] was that the molecular signature of breast cancer is
already present in the early (ADH) stage of the disease.
The genes that distinguish ADH from Normal progres-
sively change their levels away from Normal as the disease
progresses to DCIS and IDC. They also noticed that that
breast cancer progression is defined by distinct markers
for low and high grade tumors. Our results, particularly
the hierarchy we see when the data is grouped into k =
2,3,...7 clusters (Figure 2) agree with this observation.
Our methods identified six different subtypes of breast
cancer with distinct patterns of progression. Looking at
the histopathology of the samples in the clusters identi-
fied by our analysis, four of these subtypes (LG1, LG2,
HG3, HG4) have a strongly Luminal signature (predomi-
Table 2: Weighted voting classification accuracy : Sensitivity, specificity and accuracy of a weighted voting classifier in distinguishing 
samples in a given subtype from all other samples. The accuracy scores were computed using leave-one-out experiments. The genes 
used for classification were selected based on their collective power to accurately discriminate between a group and its complement.
Group Sensitivity Specificity Accuracy
LG 89.29 90.77 90.32
LG1 81.82 91.46 90.32
LG2 100.00 90.79 92.47
HG 96.88 95.08 95.70
HG1 100.00 96.59 96.77
HG2 100.00 96.39 96.77
HG3 84.62 92.50 91.40
HG4 100.00 94.38 94.62BMC Bioinformatics 2007, 8:291 http://www.biomedcentral.com/1471-2105/8/291
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Subtype heatmap using the top 10 markers Figure 4
Subtype heatmap using the top 10 markers: Red/green represent up/down regulation relative to black. Each subgroup is 
shown in a framed box to identify its samples and distinguish gene markers. The signatures of the genes specific to each sub-
type stand out distinctly compared to all other subtypes.
N LG1 LG2 HG1 HG2 HG3 HG4BMC Bioinformatics 2007, 8:291 http://www.biomedcentral.com/1471-2105/8/291
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nantly ER+, PR+, Her2-); one subtype (HG1) had the tri-
ple negative (ER-, PR-, Her2-) characteristic of the Basal-
like subtype, and one subtype (HG2) had a predomi-
nantly Her2+ signature (mixed ER, mostly Her2+). The
validation of these subtypes on a larger dataset with more
genes is currently underway.
At k = 7, each of the six BCA clusters always contained
samples in both DCIS and IDC stages from the same
patient. This strong heterogeneity in the genetic signature
of subtypes suggests that breast cancer is composed of dis-
tinct disease subtypes that develop early and progress
along different pathways because progression within a
subtype is less distinct than the subtypes themselves.
Treatment decisions may benefit by taking account of
these subtypes in addition to the current practice of using
the markers ER, PR and Her2.
Methods
Consensus ensemble clustering [18,19] was applied to the
projection of the data on the genes identified by PCA to
divide the data successively into k = 2, 3,..., kopt clusters
which were made insensitive to data and clustering
method perturbation using consensus ensemble cluster-
ing (see below). To maintain sensitivity to subtle genetic
signals, we used the full set of genes on the samples after
each k level clustering to find the best pool of genes that
distinguished a cluster from other clusters. This non-strin-
gent selection was motivated by the expectation that the
key genes altered in disease pathways are likely to have
subtle alterations in their expression levels and may not
necessarily be the same genes that are best to distinguish
the clusters. On this larger set of genes for each k, we iden-
tified two sub-classes. The first set distinguished each clus-
ter from its complement. The second set defined
progression from non-invasive to invasive disease.
Finally, we used annotated databases to identify the func-
tional pathways that are most representative of the clus-
ters identified. Each of these steps is described in detail
below.
Data normalization and imputation
The genes were normalized by first applying a robust non-
linear local regression method as described in [10] and
then by applying a global normalization procedure which
consists of subtracting the median of each gene across the
arrays. 13 genes had missing values in 13–15% of the
samples and were discarded. 105 genes had missing
entries for up to 5% of the samples. These missing entries
were imputed using a dynamical kNN approach [20].
Principal Component Analysis (PCA)
Principal Component Analysis or PCA [12,21,22] was
used to retain those genes in the dataset that contribute
most to its variance. PCA was applied to the expression
matrix Eij whose the rows were the 93 samples and whose
columns were the 1927 genes that survived after robust
imputation of missing data. The analysis was done by a
singular value decomposition of this matrix after it was
centered and scaled to mean 0 and variance 1 per column.
From the eigenvectors of the largest eigenvalues that
accounted for 85% of the variation in the data we selected
the subset of genes with coefficients in the top 25% in
absolute value in these eigenvectors. This collection of
genes was further used to find robust clusters in the data.
Ensemble consensus k-clustering
Using the genes from PCA, we first identified the optimal
number of clusters using gap statistics [11] and silhouette
scores [12]. Next, we applied an ensemble consensus k-
clustering approach (initiated by [18] and [19]) to group
the samples into the optimum number of clusters. The
ensemble consensus clustering integrates the results of
various clustering techniques across sample data perturba-
tions into a pairwise agreement matrix which is used to
partition the samples into the optimum number of clus-
ters.
The overall technique has two distinct parts: (1) a method
which generates a collection of clustering solutions using
different methods applied to many perturbations of the
Table 3: Pathways enriched in subtype clusters: Enriched functional pathways in low and high grade tumor groups and within subtypes 
using DAVID [36] using a cutoff p < 0.01.
Group Enriched pathway
LG lipid metabolism, transcriptional regulation, vesicle-mediated transport, 
amino-acid and derivative metabolism
LG1 small GTPase, mediated signal transduction, intracellular trafficking and 
vesicular transport
LG2 proteolysis collagens mRNA processing
HG mitotic cell cycle, ATM signaling pathway, role of BRCA1, BRCA2 and 
ATR in cancer susceptibility, cell cycle: G2/M checkpoint
HG1 ion transport
HG2 cell cycle proteolysis
HG3 collagens proteolysis
HG4 proteolysisBMC Bioinformatics 2007, 8:291 http://www.biomedcentral.com/1471-2105/8/291
Page 11 of 16
(page number not for citation purposes)
Low-High grade progression heatmap Figure 5
Low-High grade progression heatmap: Heatmap of expression levels of the top markers for progression from DCIS to 
IDC in the low grade and high grade tumor subgroups. In each subtype, we use the upregulated genes which have good FDR 
under WV to stratify the samples. We show the 10 top genes for DCIS to IDC progression in LG and HG tumors. Since the 
sample sizes were small, the p values were computed using permutation tests and the FDR values were computed from these 
p values. The FDR values under WV for these genes are 0.6 for LG and 0.2 for HG.
LG HGBMC Bioinformatics 2007, 8:291 http://www.biomedcentral.com/1471-2105/8/291
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DCIS to IDC progression heatmap Figure 6
DCIS to IDC progression heatmap: Heatmap of expression levels of the top 10 upregulated genes for progression from 
DCIS to IDC for each subtype. Each subgroup is in a framed box to identify its samples and distinguish gene markers. Since the 
sample sizes are small, the p values were computed using permutation tests and the FDR rates inferred from these p values. 
The FDR rates under WV for these genes are: 0.02 for LG1, 0.2 for LG2, 0.2 for HG1, 0.5 for HG2, 0.06 for HG3 and 0.002 
for HG4.
LG1 LG2 HG1 HG2 HG3 HG4BMC Bioinformatics 2007, 8:291 http://www.biomedcentral.com/1471-2105/8/291
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Pathways affected in low and high-grade tumors Figure 7
Pathways affected in low and high-grade tumors. Progression models for low and high grade tumors identified from 
functional analysis of genes characteristic of subtypes. Marker genes were placed into Hanahan-Weinberg [16] categories 
which are shown in red. Our results are in general agreement with the expectation that activation of oncogenes and loss of 
tumor suppressor genes are early events seen in low grade tumors and induction of angiogenesis is an early to mid-stage event 
seen in high grade tumors [23].
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data, and (2) a consensus function that combines the clus-
ters found to produce a single output clustering of the
data. The approach used in our paper is summarized
below.
Step 1. 150 datasets were created from the imputed data
restricted to the 207 significant genes identified by PCA.
50 datasets came from bootstrapping the samples, 50
from bootstrapping genes and 50 by first projecting the
data on bootstrapped genes and then by further boot-
strapping on samples.
Step 2. The optimal number of clusters koptwas inferred (a
priori) using the gap statistic and silhouette scores.
Step 3. k = 2,..., kopt clusters were created using represent-
ative methods from the three major classes:
(i) Partitioning: partition around medoids (PAM) [12], k-
means [23] and graph partitioning [24].
(ii) Agglomerative: hierarchical clustering based on average
linkage, complete linkage and Ward metric [12] as well as
bagglo, which is a hybrid agglomerative method devel-
oped by [24].
(iii) Probabilistic: expectation maximization (EM) method
[25], entropy-based-clustering (ENCLUST) [26], cluster-
ing on subsets of attributes (COSA) [27].
Step 4. Each clustering method was applied 50 times with
different parameter initialization on the full dataset, and
once on each of the 150 datasets from Step 1. From the
200 resulting clusters, we constructed an agreement
matrix of size Nsample × Nsample for each method, whose
entries mij represented the fraction of times a pair of sam-
ples (i, j) occurred in the same cluster out of the number
of times the pair was selected in the 200 datasets. Here
Nsample denotes the number of samples in the dataset.
Step 5. For each k, the agreement results of Step 4 were
averaged across the clustering techniques. The samples
were then sorted such that those with the highest pairwise
agreement appeared along the diagonal of the agreement
matrix in k blocks. We applied simulated annealing to
find the k optimal clusters for which the average internal
similarity (within each cluster) minus the average pair-
wise similarity (between all pairs of clusters) has a local
maximum value.
Identification of gene markers within clusters
We now used the full collection of genes on each of the
clusters identified at each k by consensus ensemble clus-
tering. The markers were chosen to discriminate between
two classes: class 1 = the group of interest (ie, the entire
cluster), class 0 = the samples not included in the group of
interest (ie, the complement of the cluster). The best
markers were identified in two steps.
Step 1. A large pool of genes which distinguished the two
labeled classes was selected based on a variant of the t-test
statistic called the signal to noise ratio (SNR) [28] with a
permutation p-value of 0.1 and a False Discovery Rate
(FDR) [29] of 0.5. The SNR statistic computes the differ-
ence of the means in each of two classes scaled by the sum
of the standard deviations: SNR = (µ0 -  µ1)/(σ0 +  σ1),
where µ0 is the mean of class 0 and σ0 is the standard devi-
ation of class 0 and so on. The t-test statistic is the same as
the SNR except that the denominator is (σ0
2 + σ1
2)1/2.
Since (σ0 + σ1) > (σ0
2 + σ1
2)1/2) SNR penalizes features
that have higher variance in each class more than those
features that have a high variance in one class and a low
variance in another. This bias is particularly useful in dis-
tinguishing genes which are altered in normal/disease or
stage/grade progression. For example, in the normal/dis-
ease case, the pathway in which the gene is involved is
working correctly in one class, and hence is regulated
strictly (has low variance) while in the other class, the
pathway is compromised and the gene is less well regu-
lated (has high variation).
Step 2. From the larger pool of genes from Step 1, we
identified the best genes correlated with the class label
using stringent criteria which combined (a) a permutation
p-value of 0.05 (b) stability to sample perturbation
through bootstrapping (c) stability to leave-one-out
experiments in top 25% genes selected by weighted voting
and kNN classifiers which distinguish the two classes with
specificity and sensitivity above 0.75. This analysis was
done using the software GenePattern from the Broad
Institute [30].
Identification of pathways and biological/functional 
categories
We used the bioinformatics public resources DAVID [31],
iHOP [32], and MatchMiner [33]. We also used 14 func-
tional annotation sources including KEGG and GO anno-
tations, Biocarta pathways, linked to DAVID as well as the
Functional Classification Tool implemented in DAVID.
The Functional Classification Tool groups genes based on
functional similarity. It uses Kappa statistics [31] which is
an index that compares the agreement against the possi-
bility that it appeared by chance. Thus,
The Kappa statistic can be thought of as the chance-cor-
rected proportional agreement, and possible values range
from +1 (perfect agreement) to 0 (no agreement above
κ=
Observed agreement - Chance agreement
1 - Chance agreement t
.BMC Bioinformatics 2007, 8:291 http://www.biomedcentral.com/1471-2105/8/291
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chance) to -1 (complete disagreement). The algorithm
first generates a gene-to-gene similarity matrix (genes in
rows and functional terms in columns) based on shared
functional annotation. The matrix is made from binary
entries. If a gene is annotated in a term, the term entry is
1, if not then the entry is 0. The algorithm adopts the
kappa statistic to quantitatively measure the degree to
which genes share similar annotation terms. The higher
the value of κ, the stronger the agreement. The Fuzzy Heu-
ristic Partition algorithm [31], which allows a gene to par-
ticipate in more than one cluster, was used to classify
highly related genes into functionally related groups.
Additional Validation
An important question is whether the gene lists found for
the subtypes identified in [5-7] and elsewhere as well as in
the present paper are sufficiently stable to have clinical
significance (be useful to analyze metastatic risk and have
consequences for drug discovery). In a recent paper [32],
a subset of the present authors reanalyzed the data of [5]
using the robust clustering techniques described above. It
was found that whereas there was sufficient clustering to
verify that the subtypes Luminal A, Luminal B, Basal-like
and Her2+ formed distinct clusters, the choice of genes in
[5] was too limited to allow a detailed study of pathways
specific to each subtype. The number of gene expressions
available in the dataset used in the present paper is also
rather limited (~1200) to make any detailed analysis of
pathways. Consequently, we have analyzed a bigger data-
set from a recent study [34] consisting of microarray data
on U133a Affymetrix chips (~22,000 genes) for 286 node
negative patients treated with radiation and surgery with
10 year clinical follow-up. This analysis will be reported in
a separate publication [35] and completely confirms the
subtypes and gene signatures found in the present paper.
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